XML 86 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition
12 Months Ended
Jun. 30, 2014
Business Combinations [Abstract]  
Acquisition
6.
  • Acquisition
On December 20, 2012, Prince Agri Products, Inc. (“Prince Agri”), a subsidiary of Phibro, acquired 100% of the membership interests of OmniGen Research, LLC (“OGR”). We acquired all rights to OmniGen-AF patents and related intellectual property and certain property, plant and equipment. OmniGen-AF is a proprietary nutritional specialty product that helps maintain a dairy cow’s healthy immune system. Prior to the transaction, Prince Agri had been the exclusive manufacturer and marketer of OmniGen-AF for 9 years, under a licensing arrangement with OGR.
The purchase price was $22,750, with an initial cash payment of $18,500 and deferred payments of $4,250. We paid $1,000 in December 2013. Annual deferred payments of $1,000 are due on or before December 20, 2014 and 2015. A final deferred payment of $1,250 is due on or before December 20, 2016. Interest is accrued and payable solely on the final installment at the rate of 5% annually from December 20, 2012 to the date of payment.
The results of the business have been included in the consolidated statements of operations since the date of acquisition. Acquired identifiable intangibles are amortized over the remaining 12-year life of the principal patents acquired. The allocation of the purchase price was:
 
Assets
 
Property, plant and equipment
$
1,202
 
Intangibles
23,781
 
Goodwill
10,896
 
Total assets
$
35,879
 
Liabilities
 
Other current and long-term liabilities
$
13,129
 
Total liabilities
13,129
 
Net assets acquired
$
22,750
 
 
In accordance with ASC 805, the excess of the purchase price over the fair values of the net assets acquired was recorded as goodwill. The goodwill is not deductible for U.S. federal or state income taxes.
OGR’s only revenues were the royalties paid by Prince Agri. As a result, our operating results benefited from the elimination of the royalties previously paid to OGR, net of operating expenses related to acquired research and development activities. The unaudited pro forma consolidated results of operations, as if such acquisition had occurred at the beginning of the fiscal year ended June 30, 2012, are as follows:
 
For the Years Ended June 30
2013
2012
Net sales
$
653,151
 
$
654,101
 
Net income (loss)
25,989
 
9,170
 
Net income (loss) per share−basic and diluted
0.85
 
0.30
 
Adjusted EBITDA
77,731
 
70,804